{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T21:39:58Z","timestamp":1793741998605,"version":"4.6.1"},"reference-count":99,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T00:00:00Z","timestamp":1694131200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P01CA214278"],"award-info":[{"award-number":["P01CA214278"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U54CA244711"],"award-info":[{"award-number":["U54CA244711"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunity"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.immuni.2023.09.001","type":"journal-article","created":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T10:35:37Z","timestamp":1695983737000},"page":"2388-2407.e9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":193,"title":["Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T\u00a0cells"],"prefix":"10.1016","volume":"56","author":[{"given":"Sangya","family":"Agarwal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Angela","family":"Aznar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Rech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charly R.","family":"Good","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunichiro","family":"Kuramitsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Da","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercy","family":"Gohil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linhui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seok-Jae Albert","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pranali","family":"Ravikumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Austin K.","family":"Rennels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"January","family":"Salas-Mckee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weimin","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Ruella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan M.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Plesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph A.","family":"Fraietta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Porter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina M.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0241-3557","authenticated-orcid":false,"given":"Carl H.","family":"June","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.immuni.2023.09.001_bib1","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and Toxicity Management of 19\u201328z CAR T\u00a0cell Therapy in B\u00a0cell Acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.immuni.2023.09.001_bib2","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.immuni.2023.09.001_bib3","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.immuni.2023.09.001_bib4","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1158\/2159-8290.CD-21-1683","article-title":"Next-generation CAR T-cell therapies","volume":"12","author":"Young","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.immuni.2023.09.001_bib5","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1200\/JCO.20.03585","article-title":"Disease burden affects outcomes in pediatric and young adult B-cell lymphoblastic leukemia after commercial tisagenlecleucel: A pediatric real-world chimeric antigen receptor consortium report","volume":"40","author":"Schultz","year":"2022","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.immuni.2023.09.001_bib6","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.csbj.2016.09.003","article-title":"Catch me if you can: leukemia escape after CD19-directed T\u00a0cell immunotherapies","volume":"14","author":"Ruella","year":"2016","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"10.1016\/j.immuni.2023.09.001_bib7","article-title":"A review of CAR T-cell therapies approved for the treatment of relapsed and refractory B-cell lymphomas","volume":"12","author":"Wells","year":"2022","journal-title":"J.\u00a0Hematol. Oncol. Pharm."},{"key":"10.1016\/j.immuni.2023.09.001_bib8","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.immuni.2023.09.001_bib9","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1182\/blood.2021011895","article-title":"Phase 1 Transcend CLL 004 study of lisocabtagene maraleucel in patients with relapsed\/refractory CLL or SLL","volume":"139","author":"Siddiqi","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.immuni.2023.09.001_bib10","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1200\/JCO.19.03237","article-title":"Long-term outcomes from a randomized dose optimization study of chimeric antigen receptor modified T\u00a0cells in relapsed chronic lymphocytic leukemia","volume":"38","author":"Frey","year":"2020","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.immuni.2023.09.001_bib11","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.immuni.2023.09.001_bib12","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/j.ymthe.2020.12.033","article-title":"Leukemic extracellular vesicles induce chimeric antigen receptor T\u00a0cell dysfunction in chronic lymphocytic leukemia","volume":"29","author":"Cox","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.immuni.2023.09.001_bib13","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T\u00a0cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.immuni.2023.09.001_bib14","doi-asserted-by":"crossref","first-page":"562","DOI":"10.3324\/haematol.2016.151100","article-title":"T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers","volume":"102","author":"Palma","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.immuni.2023.09.001_bib15","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1182\/blood.2018885863","article-title":"Chronic lymphocytic leukemia cells imapir mitochondrial fitness in CD8+ T\u00a0cells and impede CAR T\u00a0cell efficacy","volume":"134","author":"van Bruggen","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.immuni.2023.09.001_bib16","doi-asserted-by":"crossref","DOI":"10.1172\/JCI145459","article-title":"BET bromodomain protein inhibition reverses chimeric antigen receptor extinction and reinvigorates exhausted T\u00a0cells in chronic lymphocytic leukemia","volume":"131","author":"Kong","year":"2021","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.immuni.2023.09.001_bib17","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti\u2013PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.immuni.2023.09.001_bib18","article-title":"Immunotherapy of non-Hodgkin\u2019s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor\u2013modified T\u00a0cells","volume":"8","author":"Turtle","year":"2016","journal-title":"Sci. Tranl. Med."},{"key":"10.1016\/j.immuni.2023.09.001_bib19","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.immuni.2023.09.001_bib20","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.immuni.2023.09.001_bib21","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.cell.2017.07.024","article-title":"Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade","volume":"170","author":"Wei","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2023.09.001_bib22","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.immuni.2023.09.001_bib23","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.omto.2016.11.005","article-title":"Enhancement of PSMA-directed CAR adoptive immunotherapy by PD-1\/PD-L1 blockade","volume":"4","author":"Serganova","year":"2017","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.immuni.2023.09.001_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.858021","article-title":"Anti-PD-1 therapy enhances the efficacy of CD30-directed chimeric antigen receptor T\u00a0cell therapy in patients with relapsed\/refractory CD30+ lymphoma","volume":"13","author":"Sang","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.immuni.2023.09.001_bib25","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.omto.2018.08.002","article-title":"Checkpoint blockade reverses anergy in IL-13Ralpha2 humanized scFv-based CAR T\u00a0cells to treat murine and canine gliomas","volume":"11","author":"Yin","year":"2018","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.immuni.2023.09.001_bib26","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1158\/2159-8290.CD-21-0407","article-title":"A Phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab","volume":"11","author":"Adusumilli","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.immuni.2023.09.001_bib27","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1182\/blood.2021012634","article-title":"Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy","volume":"139","author":"Chong","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.immuni.2023.09.001_bib28","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1182\/blood-2018-99-112572","article-title":"Checkpoint inhibitors augment CD19-directed chimeric antigen receptor (CAR) T\u00a0cell therapy in relapsed B-cell acute lymphoblastic leukemia","volume":"132","author":"Li","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.immuni.2023.09.001_bib29","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1126\/science.aaf1292","article-title":"T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition","volume":"355","author":"Hui","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.immuni.2023.09.001_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00630","article-title":"PD-1 primarily targets TCR signal in the inhibition of functional T\u00a0cell activation","volume":"10","author":"Mizuno","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.immuni.2023.09.001_bib31","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1158\/1078-0432.CCR-16-1300","article-title":"Multiplex genome editing to generate universal CAR T\u00a0cells resistant to PD1 inhibition","volume":"23","author":"Ren","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.immuni.2023.09.001_bib32","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/s41598-017-00462-8","article-title":"CRISPR\/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T\u00a0cells","volume":"7","author":"Rupp","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.immuni.2023.09.001_bib33","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/s40425-019-0685-y","article-title":"PD-1 silencing impairs the anti-tumor function of chimeric antigen receptor modified T\u00a0cells by inhibiting proliferation activity","volume":"7","author":"Wei","year":"2019","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.immuni.2023.09.001_bib34","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.gene.2017.09.010","article-title":"CRISPR knock out CTLA-4 enhances the anti-tumor activity of cytotoxic T lymphocytes","volume":"636","author":"Shi","year":"2017","journal-title":"Gene"},{"key":"10.1016\/j.immuni.2023.09.001_bib35","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s00280-019-03800-x","article-title":"Disruption of CTLA-4 expression on peripheral blood CD8\u00a0+ T\u00a0cell enhances anti-tumor efficacy in bladder cancer","volume":"83","author":"Zhang","year":"2019","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.immuni.2023.09.001_bib36","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/exd.13678","article-title":"The siRNA-mediated downregulation of PD-1 alone or simultaneously with CTLA-4 shows enhanced in\u00a0vitro CAR-T-cell functionality for further clinical development towards the potential use in immunotherapy of melanoma","volume":"27","author":"Simon","year":"2018","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.immuni.2023.09.001_bib37","doi-asserted-by":"crossref","DOI":"10.1126\/science.aba7365","article-title":"CRISPR-engineered T\u00a0cells in patients with refractory cancer","volume":"367","author":"Stadtmauer","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.immuni.2023.09.001_bib38","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/s41591-020-0840-5","article-title":"Safety and feasibility of CRISPR-edited T\u00a0cells in patients with refractory non-small-cell lung cancer","volume":"26","author":"Lu","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.immuni.2023.09.001_bib39","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.coi.2021.10.008","article-title":"Better living through chemistry: CRISPR\/Cas engineered T\u00a0cells for cancer immunotherapy","volume":"74","author":"Wellhausen","year":"2022","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.immuni.2023.09.001_bib40","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/s41577-019-0221-9","article-title":"Defining 'T cell exhaustion'","volume":"19","author":"Blank","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.immuni.2023.09.001_bib41","doi-asserted-by":"crossref","first-page":"6081","DOI":"10.1016\/j.cell.2021.11.016","article-title":"An NK-like CAR T\u00a0cell transition in CAR T\u00a0cell dysfunction","volume":"184","author":"Good","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2023.09.001_bib42","doi-asserted-by":"crossref","DOI":"10.3791\/62299","article-title":"Production of human CRISPR-engineered CAR-T cells","author":"Agarwal","year":"2021","journal-title":"J.\u00a0Vis. Exp."},{"key":"10.1016\/j.immuni.2023.09.001_bib43","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1038\/mt.2009.83","article-title":"Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T\u00a0cells and increased antileukemic efficacy in\u00a0vivo","volume":"17","author":"Milone","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.immuni.2023.09.001_bib44","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/362248a0","article-title":"lnterleukin-13 is a new human lymphokine regulating inflammatory and immune responses","volume":"362","author":"Minty","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2023.09.001_bib45","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/s41435-020-00118-0","article-title":"Genomic profiling of T-cell activation suggests increased sensitivity of memory T\u00a0cells to CD28 costimulation","volume":"21","author":"Glinos","year":"2020","journal-title":"Genes Immun."},{"key":"10.1016\/j.immuni.2023.09.001_bib46","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002098","article-title":"A role for the chemokine RANTES in regulating CD8 T\u00a0cell responses during chronic viral infection","volume":"7","author":"Crawford","year":"2011","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.immuni.2023.09.001_bib47","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-34156-1","article-title":"Differential trafficking of ligands trogocytosed via CD28 versus CTLA4 promotes collective cellular control of co-stimulation","volume":"13","author":"Zenke","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.immuni.2023.09.001_bib48","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1126\/science.1202947","article-title":"Trans-endocytosis of CD80 and CD86: A molecular basis for the cell-extrinsic function of CTLA-4","volume":"332","author":"Qureshi","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.immuni.2023.09.001_bib49","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1158\/1078-0432.CCR-10-0569","article-title":"Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial","volume":"16","author":"Carthon","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.immuni.2023.09.001_bib50","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.immuni.2020.07.011","article-title":"Chimeric antigen receptor designed to prevent ubiquitination and downregulation showed durable antitumor efficacy","volume":"53","author":"Li","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2023.09.001_bib51","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/ni.1835","article-title":"CTLA-4 suppresses the pathogenicity of self antigen-specific T\u00a0cells by cell-intrinsic and cell-extrinsic mechanisms","volume":"11","author":"Ise","year":"2010","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.immuni.2023.09.001_bib52","doi-asserted-by":"crossref","first-page":"E2383","DOI":"10.1073\/pnas.1603892113","article-title":"Induction of autoimmune disease by deletion of CTLA-4 in mice in adulthood","volume":"113","author":"Klocke","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.immuni.2023.09.001_bib53","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/nri3108","article-title":"The emerging role of CTLA4 as a cell-extrinsic regulator of T\u00a0cell responses","volume":"11","author":"Walker","year":"2011","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.immuni.2023.09.001_bib54","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41586-019-1805-z","article-title":"C-Jun overexpression in CAR T\u00a0cells induces exhaustion resistance","volume":"576","author":"Lynn","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2023.09.001_bib55","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.cell.2017.05.035","article-title":"Landscape of infiltrating T\u00a0cells in liver cancer revealed by single-cell sequencing","volume":"169","author":"Zheng","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2023.09.001_bib56","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1038\/s41591-018-0045-3","article-title":"Global characterization of T\u00a0cells in non-small-cell lung cancer by single-cell sequencing","volume":"24","author":"Guo","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.immuni.2023.09.001_bib57","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.cell.2018.11.043","article-title":"Dysfunctional CD8 T\u00a0cells form a proliferative, dynamically regulated compartment within human melanoma","volume":"176","author":"Li","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2023.09.001_bib58","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.immuni.2007.09.006","article-title":"Molecular signature of CD8+ T\u00a0cell exhaustion during chronic viral infection","volume":"27","author":"Wherry","year":"2007","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2023.09.001_bib59","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.immuni.2020.04.014","article-title":"Developmental relationships of four exhausted CD8(+) T\u00a0cell subsets reveals underlying transcriptional and epigenetic landscape control mechanisms","volume":"52","author":"Beltra","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2023.09.001_bib60","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.it.2015.02.008","article-title":"Overcoming T\u00a0cell exhaustion in infection and cancer","volume":"36","author":"Pauken","year":"2015","journal-title":"Trends Immunol."},{"key":"10.1016\/j.immuni.2023.09.001_bib61","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.ccell.2018.03.012","article-title":"T cell dysfunction in cancer","volume":"33","author":"Thommen","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.immuni.2023.09.001_bib62","doi-asserted-by":"crossref","DOI":"10.1126\/science.aba1786","article-title":"Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling","volume":"372","author":"Weber","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.immuni.2023.09.001_bib63","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.728771","article-title":"CTLA-4 facilitates DNA damage-induced apoptosis by interacting with PP2A","volume":"10","author":"Yan","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.immuni.2023.09.001_bib64","series-title":"Orthogonal CRISPR screens to identify transcriptional and epigenetic regulators of human CD8 T\u00a0cell function","author":"McCutcheon","year":"2023"},{"key":"10.1016\/j.immuni.2023.09.001_bib65","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41586-021-04390-6","article-title":"Decade-long leukaemia remissions with persistence of CD4(+) CAR T\u00a0cells","volume":"602","author":"Melenhorst","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2023.09.001_bib66","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0130518","article-title":"Tumor-targeted human T\u00a0cells expressing CD28-based chimeric antigen receptors circumvent CTLA-4 inhibition","volume":"10","author":"Condomines","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.immuni.2023.09.001_bib67","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.it.2014.12.001","article-title":"Confusing signals: recent progress in CTLA-4 biology","volume":"36","author":"Walker","year":"2015","journal-title":"Trends Immunol."},{"key":"10.1016\/j.immuni.2023.09.001_bib68","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1038\/s41590-022-01289-w","article-title":"Differences in CD80 and CD86 transendocytosis reveal CD86 as a key target for CTLA-4 immune regulation","volume":"23","author":"Kennedy","year":"2022","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.immuni.2023.09.001_bib69","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1146\/annurev.immunol.24.021605.090535","article-title":"A molecular perspective of CTLA-4 function","volume":"24","author":"Teft","year":"2006","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.immuni.2023.09.001_bib70","doi-asserted-by":"crossref","first-page":"4262","DOI":"10.1158\/1078-0432.CCR-13-2627","article-title":"Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T\u00a0cells in solid tumors","volume":"20","author":"Moon","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.immuni.2023.09.001_bib71","doi-asserted-by":"crossref","first-page":"5784","DOI":"10.4049\/jimmunol.162.10.5784","article-title":"Lymphoproliferative disorder in CTLA-4 knockout mice is characterized by CD28-regulated activation of Th2 responses","volume":"162","author":"Khattri","year":"1999","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.immuni.2023.09.001_bib72","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/1074-7613(95)90125-6","article-title":"Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4","volume":"3","author":"Tivol","year":"1995","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2023.09.001_bib73","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1084\/jem.20141030","article-title":"Deletion of CTLA-4 on regulatory T\u00a0cells during adulthood leads to resistance to autoimmunity","volume":"212","author":"Paterson","year":"2015","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.immuni.2023.09.001_bib74","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1126\/science.1255904","article-title":"Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4","volume":"345","author":"Kuehn","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.immuni.2023.09.001_bib75","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/nm.3746","article-title":"Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations","volume":"20","author":"Schubert","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.immuni.2023.09.001_bib76","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/s41577-022-00693-5","article-title":"The link between circulating follicular helper T\u00a0cells and autoimmunity","volume":"22","author":"Walker","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.immuni.2023.09.001_bib77","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.immuni.2019.01.006","article-title":"Clonal deletion of tumor-specific T\u00a0cells by interferon-gamma confers therapeutic resistance to combination immune checkpoint blockade","volume":"50","author":"Pai","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2023.09.001_bib78","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1158\/2159-8290.CD-20-1680","article-title":"The next decade of immune checkpoint therapy","volume":"11","author":"Sharma","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.immuni.2023.09.001_bib79","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2200626120","article-title":"Long-term persistence and functionality of adoptively transferred antigen-specific T\u00a0cells with genetically ablated PD-1 expression","volume":"120","author":"D\u00f6tsch","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.immuni.2023.09.001_bib80","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2021.745286","article-title":"Engineered removal of PD-1 from the surface of CD19 CAR-T cells results in increased activation and diminished survival","volume":"8","author":"Kalinin","year":"2021","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.immuni.2023.09.001_bib81","doi-asserted-by":"crossref","first-page":"872756","DOI":"10.3389\/fimmu.2022.872756","article-title":"PD1 expression in EGFRvIII-directed CAR T\u00a0cell infusion product for glioblastoma is associated with clinical response","volume":"13","author":"Tang","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.immuni.2023.09.001_bib82","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1084\/jem.20142237","article-title":"Genetic absence of PD-1 promotes accumulation of terminally differentiated exhausted CD8+ T\u00a0cells","volume":"212","author":"Odorizzi","year":"2015","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.immuni.2023.09.001_bib83","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/mt.2009.210","article-title":"Chimeric antigen receptors combining 4\u20131BB and CD28 signaling domains augment PI3kinase\/AKT\/Bcl-XL activation and CD8+ T\u00a0cell-mediated tumor eradication","volume":"18","author":"Zhong","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.immuni.2023.09.001_bib84","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41586-019-1054-1","article-title":"CAR T\u00a0cell trogocytosis and cooperative killing regulate tumour antigen escape","volume":"568","author":"Hamieh","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2023.09.001_bib85","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/s41590-020-0620-x","article-title":"PD-L1 engagement on T\u00a0cells promotes self-tolerance and suppression of neighboring macrophages and effector T\u00a0cells in cancer","volume":"21","author":"Diskin","year":"2020","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.immuni.2023.09.001_bib86","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1126\/science.aav7062","article-title":"Restriction of PD-1 function by cis-PD-L1\/CD80 interactions is required for optimal T\u00a0cell responses","volume":"364","author":"Sugiura","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.immuni.2023.09.001_bib87","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2022111556","article-title":"The CTLA-4 immune checkpoint\u00a0protein regulates PD-L1:PD-1 interaction via transendocytosis of its ligand CD80","volume":"42","author":"Kennedy","year":"2023","journal-title":"EMBO J."},{"key":"10.1016\/j.immuni.2023.09.001_bib88","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.immuni.2023.04.005","article-title":"cis-B7:CD28 interactions at invaginated synaptic membranes provide CD28 co-stimulation and promote CD8(+) T\u00a0cell function and anti-tumor immunity","volume":"56","author":"Zhao","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2023.09.001_bib89","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/nbt.4096","article-title":"Integrating single-cell transcriptomic data across different conditions, technologies, and species","volume":"36","author":"Butler","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.immuni.2023.09.001_bib90","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1016\/j.cell.2019.05.031","article-title":"Comprehensive integration of single-cell data","volume":"177","author":"Stuart","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2023.09.001_bib91","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1186\/s13059-019-1874-1","article-title":"Normalization and variance stabilization of single-cell RNA-seq data using regularized negative binomial regression","volume":"20","author":"Hafemeister","year":"2019","journal-title":"Genome Biol."},{"key":"10.1016\/j.immuni.2023.09.001_bib92","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol."},{"key":"10.1016\/j.immuni.2023.09.001_bib93","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","article-title":"edgeR: a Bioconductor package for differential expression analysis of digital gene expression data","volume":"26","author":"Robinson","year":"2010","journal-title":"Bioinformatics"},{"key":"10.1016\/j.immuni.2023.09.001_bib94","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nprot.2009.22","article-title":"Production, concentration and titration of pseudotyped HIV-1-based lentiviral vectors","volume":"4","author":"Kutner","year":"2009","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.immuni.2023.09.001_bib95","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T\u00a0cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.immuni.2023.09.001_bib96","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1093\/nar\/gku936","article-title":"Easy quantitative assessment of genome editing by sequence trace decomposition","volume":"42","author":"Brinkman","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.immuni.2023.09.001_bib97","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13059-019-1625-3","article-title":"iGUIDE: an improved pipeline for analyzing CRISPR cleavage specificity","volume":"20","author":"Nobles","year":"2019","journal-title":"Genome Biol."},{"key":"10.1016\/j.immuni.2023.09.001_bib98","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/trf.12279","article-title":"Infusion of clinical-grade enriched regulatory T\u00a0cells delays experimental xenogeneic graft-versus-host disease","volume":"54","author":"Hannon","year":"2014","journal-title":"Transfusion"},{"key":"10.1016\/j.immuni.2023.09.001_bib99","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1093\/bioinformatics\/btaa751","article-title":"Systematic determination of the mitochondrial proportion in human and mice tissues for single-cell RNA-sequencing data quality control","volume":"37","author":"Osorio","year":"2021","journal-title":"Bioinformatics"}],"container-title":["Immunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1074761323004077?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1074761323004077?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T08:24:49Z","timestamp":1761035089000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1074761323004077"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":99,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S1074761323004077"],"URL":"https:\/\/doi.org\/10.1016\/j.immuni.2023.09.001","relation":{},"ISSN":["1074-7613"],"issn-type":[{"value":"1074-7613","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T\u00a0cells","name":"articletitle","label":"Article Title"},{"value":"Immunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.immuni.2023.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}